Company profile

Pathos

Pathos has raised a total of $345 million across multiple funding rounds, including a $283 million Series D in April 2025 led by New Enterprise Associates and Revolution. Founded in 2022 and headquartered in Chicago, Pathos achieved unicorn status in just 3 years and 4 months, with a valuation of $1.6 billion. The company leverages AI and patient-derived genomic data to accelerate biomarker-driven drug discovery, optimize clinical-stage therapeutics, and improve patient outcomes, positioning itself as a leading innovator in life sciences and oncology technology.

Back to profiles

Quick facts

Total funding: $345 million
Valuation: $1.6 billion
Founded: 2022
Headquarters: Chicago, Pathos achieved unicorn status in just 3 years and 4 months

Notable investors

New Enterprise Associates
Revolution

Reach buyers like Pathos on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Pathos
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Pathos.

The 14-day trial ships every feature, no card required.

Start free →